Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: Pooled analysis of three double-blind, randomized, crossover, multicenter studies
Neurological Sciences, ISSN: 1590-1874, Vol: 33, Issue: SUPPL. 1, Page: S65-9
2012
- 22Citations
- 33Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations22
- Citation Indexes20
- 20
- CrossRef9
- Policy Citations2
- 2
- Captures33
- Readers33
- 33
Conference Paper Description
The objective of this study was to review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), in women with menstrually related migraine (IHS criteria) through a pooled analysis of three individual studies. Subjects with a history of migraine with or without aura were randomized to F 2.5 mg or R 10 mg (study 1), F or Z 2.5 mg (study 2), and F or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double-blind, crossover design. After treating three episodes of migraine in no more than 3 months with the first treatment, patients had to switch to the next treatment for other 3 months. 346 subjects formed intention-to-treat population of the main study; 280 of them were of a female gender, 256 had regular menses and 187 were included in the menstrual migraine subgroup analysis. Rate of pain free at 2, 4 and 24 h was 23, 52 and 67 % with F and 30, 61 and 66 % with comparators (P = NS). Pain relief episodes at 2, 4 and 24 h were 37, 60 and 66 % for F and 43, 55 and 61 % for comparators (P = NS). Rate of recurrence was significantly (P<0.05) lower under F either at 24 h (11 vs. 24 % comparators) or at 48 h (15 vs. 26 % comparators). Number of menstrual migraine attacks associated with drug-related adverse events was equally low (P = NS) between F (5 %) and comparators (4 %). © The Author(s) 2012.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84864275291&origin=inward; http://dx.doi.org/10.1007/s10072-012-1044-7; http://www.ncbi.nlm.nih.gov/pubmed/22644174; http://link.springer.com/10.1007/s10072-012-1044-7; http://www.springerlink.com/index/10.1007/s10072-012-1044-7; http://www.springerlink.com/index/pdf/10.1007/s10072-012-1044-7; https://dx.doi.org/10.1007/s10072-012-1044-7; https://link.springer.com/article/10.1007/s10072-012-1044-7; http://europepmc.org/abstract/med/22644174; http://europepmc.org/articles/PMC3362699; http://link.springer.com/article/10.1007%2Fs10072-012-1044-7; https://link.springer.com/content/pdf/10.1007%2Fs10072-012-1044-7.pdf
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know